Selective binding site for [3H]prostacyclin on platelets.

Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond) (2008) 1.53

Desensitization of prostacyclin responsiveness in a neuronal hybrid cell line: selective loss of high affinity receptors. Br J Pharmacol (1985) 1.10

Apical-basolateral membrane asymmetry in canine cortical collecting tubule cells. Bradykinin, arginine vasopressin, prostaglandin E2 interrelationships. J Clin Invest (1984) 1.06

Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets. Br J Pharmacol (1986) 1.05

The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase. Br J Pharmacol (1989) 1.02

The binding of [3H]-prostacyclin to membranes of a neuronal somatic hybrid. Br J Pharmacol (1981) 1.00

Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol (1993) 0.97

Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets. Br J Pharmacol (1985) 0.93

Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders. J Clin Invest (1979) 0.92

Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets. Biochem J (1984) 0.92

Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C. Br J Pharmacol (1989) 0.90

Desensitization of prostacyclin receptors in a neuronal hybrid cell line. Br J Pharmacol (1982) 0.89

The prostanoids in hemostasis and thrombosis: a review. Am J Pathol (1980) 0.83

Prostaglandin-concentration-dependent desensitization of adenylate cyclase in human erythroleukaemia (HEL) cells is abolished by pertussis toxin and enhanced by induction by dimethyl sulphoxide. Biochem J (1991) 0.83

Platelets of pseudohypoparathyroid patients: evidence that distinct receptor-cyclase coupling proteins mediate stimulation and inhibition of adenylate cyclase. Proc Natl Acad Sci U S A (1982) 0.81

A comparative study of the prostanoid receptor profile of 9 alpha 11 beta-prostaglandin F2 and prostaglandin D2. Br J Pharmacol (1991) 0.79

Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. Proc Natl Acad Sci U S A (1996) 0.79

The effect of low-density lipoproteins on the synthesis of cyclic nucleotides induced by prostacyclin in isolated platelets. Biochem J (1984) 0.79

Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Br J Clin Pharmacol (1983) 0.78

Prostaglandin E(2) increases cyclic AMP and inhibits endothelin-1 production/secretion by guinea-pig tracheal epithelial cells through EP(4) receptors. Br J Pharmacol (2001) 0.77

Demonstration of a novel circulating anti-prostacyclin receptor antibody. Proc Natl Acad Sci U S A (1997) 0.76

Lower-extremity functional electrical stimulation decreases platelet aggregation and blood coagulation in persons with chronic spinal cord injury: a pilot study. J Spinal Cord Med (2010) 0.76

Classification of prostaglandin receptors based on coupling to signal transduction systems. Biochem J (1989) 0.75

Low concentrations of prostaglandin E2 inhibit the prostacyclin-induced elevation of cyclic adenosine 3',5'-monophosphate in elicited populations of rat peritoneal macrophages. Br J Pharmacol (1982) 0.75

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44

Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80

Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74

Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A (1977) 3.74

The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63

Properties of graphical representations of multiple classes of binding sites. Biochemistry (1971) 3.20

Localisation and stimulation of prostacyclin production in vascular cells. Nature (1978) 2.45

Prostaglandin D2 inhibits the aggregation of human platelets. Thromb Res (1974) 2.35

Cooperative properties of hormone receptors in cell membranes. J Supramol Struct (1976) 1.43

Stimulation of human platelet adenylate cyclase by prostaglandin D2. Thromb Res (1974) 1.26

Interaction of prostaglandins E1 and E2 in regulation of cyclic-AMP and aggregation in human platelets: evidence for a common prostaglandin receptor. J Lab Clin Med (1974) 0.98

Rapid and easy preparation of prostacyclin. Lancet (1977) 0.92

Are prostaglandins intracellular, transcellular or extracellular autocoids? Prostaglandins (1975) 0.92

Discrete prostaglandin receptors in the outer cell membranes of bovine corpora lutea. Adv Prostaglandin Thromboxane Res (1976) 0.82

Characteristics of prostaglandin receptor sites in human uterine tissue. Adv Prostaglandin Thromboxane Res (1976) 0.82

Nuclear dna amounts in angiosperms. Philos Trans R Soc Lond B Biol Sci (1976) 10.59

Antibody formation by single cells from lymph nodes and efferent lymph of sheep. J Exp Med (1966) 8.86

Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol (1971) 7.75

Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med (1998) 4.08

Genome size and the proportion of repeated nucleotide sequence DNA in plants. Biochem Genet (1974) 3.66

A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell (2003) 2.85

Metabolism of [14C]arachidonic acid by human platelets. Biochim Biophys Acta (1976) 2.61

Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem (2000) 2.53

Prostaglandin D2 inhibits the aggregation of human platelets. Thromb Res (1974) 2.35

Serum stimulates the Na+,K+ pump in quiescent fibroblasts by increasing Na+ entry. Proc Natl Acad Sci U S A (1978) 2.29

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res (2002) 2.27

The traffic of cells through tissues: a study of peripheral lymph in sheep. J Anat (1970) 2.24

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A (2000) 2.20

The major in vivo modifications of the human water-insoluble lens crystallins are disulfide bonds, deamidation, methionine oxidation and backbone cleavage. Exp Eye Res (2000) 2.10

Japanese yew poisoning of large domestic animals in the Midwest. J Am Vet Med Assoc (1977) 2.07

Perirenal edema and toxic nephrosis in cattle, associated with ingestion of pigweed. J Am Vet Med Assoc (1975) 2.04

The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets. Biochem J (1971) 2.04

Formation of prostaglandins during the aggregation of human blood platelets. J Clin Invest (1973) 1.96

Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem (1998) 1.93

The migration of cells through chronically inflamed tissues. J Pathol (1970) 1.92

Arachidonic acid causes sudden death in rabbits. Science (1974) 1.91

Activation of suppressor T cells in human autologous mixed lymphocyte culture. J Immunol (1979) 1.90

Age-related changes in human lens crystallins identified by two-dimensional electrophoresis and mass spectrometry. Exp Eye Res (1998) 1.88

Malondialdehyde formation as an indicator of prostaglandin production by human platelets. J Lab Clin Med (1976) 1.86

Selective release of archidonic acid from the phospholipids of human platelets in response to thrombin. J Clin Invest (1977) 1.84

Sequence analysis of betaA3, betaB3, and betaA4 crystallins completes the identification of the major proteins in young human lens. J Biol Chem (1997) 1.84

Reevaluation of ampicillin therapy for Hemophilus influenzae meningitis. An appraisal based on a review of cases of persistent or recurrent infection. Am J Dis Child (1971) 1.82

Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res (1999) 1.82

Formation of an intermediate in prostaglandin biosynthesis and its association with the platelet release reaction. J Clin Invest (1974) 1.76

Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. Am J Cardiol (2000) 1.69

Arachidonic acid-induced human platelet aggregation and prostaglandin formation. Prostaglandins (1973) 1.69

The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocorticoid regulation in endotoxemia. J Leukoc Biol (1998) 1.67

Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67

Syngeneic mixed lymphocyte reaction in mice: strain distribution, kinetics, participating cells, and absence in NZB mice. J Immunol (1978) 1.67

The carbon dioxide rate of rise in awake apneic humans. J Clin Anesth (1988) 1.65

Synthesis and biological properties of a 9,11-azo-prostanoid: highly active biochemical mimic of prostaglandin endoperoxides. Proc Natl Acad Sci U S A (1975) 1.64

Ischemia-reperfusion of rat myocardium activates nuclear factor-KappaB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation (2001) 1.63

Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science (1978) 1.62

Formation and release of prostaglandins by platelets in response to thrombin. Br J Pharmacol (1970) 1.59

Carbodiimide-resistant membrane adenosine triphosphatase in mutants of Streptococcus faecalis. I. Studies of the mechanism of resistance. J Biol Chem (1972) 1.58

Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis (1990) 1.58

Bovine endothelial cells in culture produce thromboxane as well as prostacyclin. J Clin Invest (1981) 1.58

Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation (1980) 1.56

Age-related changes in human lens crystallins identified by HPLC and mass spectrometry. Exp Eye Res (1998) 1.53

Post-translational modifications of water-soluble human lens crystallins from young adults. J Biol Chem (1994) 1.53

Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol (1989) 1.52

Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci U S A (1980) 1.52

Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci U S A (1986) 1.51

Purification of membrane attachment and inhibitory subunits of the proton translocating adenosine triphosphatase from Escherichia coli. Biochemistry (1977) 1.49

Cardiac and renal prostaglandin I2. Biosynthesis and biological effects in isolated perfused rabbit tissues. J Clin Invest (1978) 1.48

Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol (1979) 1.47

Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci U S A (1979) 1.47

Identification of possible regions of chaperone activity in lens alpha-crystallin. Exp Eye Res (1996) 1.46

Chemical self-replication of palindromic duplex DNA. Nature (1994) 1.46

Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem Biol (2004) 1.46

Conformation of a water-soluble derivative of taxol in water by 2D-NMR spectroscopy. Chem Biol (1994) 1.44

Influence of a randomized clinical trial on practice by participating investigators: lessons from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). CAVEAT I and II Investigators. J Am Coll Cardiol (1998) 1.42

Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence. J Clin Invest (1979) 1.39

Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin. Prostaglandins (1973) 1.39

Epilepsy health consumer groups and charities; how representative of patients are they? The results of a pilot study. Seizure (2012) 1.38

Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther (1983) 1.38

Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol (2006) 1.36

Stress and developmental regulation of the yeast C-type cyclin Ume3p (Srb11p/Ssn8p). EMBO J (1997) 1.35

Human blood prostaglandins: formation during clotting. Prostaglandins (1972) 1.35

Formation of lysophosphatidylcholine by human platelets in response to thrombin. Support for the phospholipase A2 pathway for the liberation of arachidonic acid. J Biol Chem (1981) 1.34

Immunologic studies in chronic lymphocytic leukemia: defective stimulation of T-cell proliferation in autologous mixed lymphocyte culture. J Natl Cancer Inst (1977) 1.34

Stimulation of autologous and allogeneic human T cells by B cells occurs through separate B-cell antigen systems. Cell Immunol (1978) 1.33

Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33

Deamidation and disulfide bonding in human lens gamma-crystallins. Exp Eye Res (1998) 1.31

Temperature and nucleotide dependence of calcium release by myo-inositol 1,4,5-trisphosphate in cultured vascular smooth muscle cells. J Biol Chem (1985) 1.30

Modifications of the water-insoluble human lens alpha-crystallins. Exp Eye Res (1996) 1.30

Characterization of a binding site for chemically synthesized lipo-oligosaccharidic NodRm factors in particulate fractions prepared from roots. Plant J (1995) 1.29

The enediyne antibiotics. J Med Chem (1996) 1.29

Cytogenetics of fetal abortions. Pediatrics (1967) 1.29

The relationship of brevetoxin 'length' and A-ring functionality to binding and activity in neuronal sodium channels. Chem Biol (1995) 1.28

Size of human lens beta-crystallin aggregates are distinguished by N-terminal truncation of betaB1. J Biol Chem (1997) 1.25

The role of the lymphatic system and lymphoid cells in the establishment of immunological memory. Aust J Exp Biol Med Sci (1970) 1.24

Protein tyrosine phosphorylation induced via the IgG receptors Fc gamma Ri and Fc gamma RII in the human monocytic cell line THP-1. J Immunol (1992) 1.24

Taxoids: new weapons against cancer. Sci Am (1996) 1.23

Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol (1982) 1.23

Use of a radioimmunoassay to study thrombin-induced release of PGI2 from cultured endothelium. Thromb Res (1979) 1.22